

# AvMed

## MEDICAL PRIOR AUTHORIZATION/STEP-EDIT REQUEST\*

**Directions:** The prescribing physician must sign and clearly print name (preprinted stamps not valid) on this request. All other information may be filled in by office staff; fax to 1-877-535-1391. No additional phone calls will be necessary if all information (including phone and fax #s) on this form is correct. If information provided is not complete, correct, or legible, authorization can be delayed.

**For Medicare Members:** Medicare Coverage for outpatient (Part B) drugs is outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals. In addition, National Coverage Determination (NCD) and Local Coverage Determinations (LCDs) may exist and compliance with these policies is required where applicable. They can be found at: <https://www.cms.gov/medicare-coverage-database/overview-and-quick-search.aspx>. Additional indications may be covered at the discretion of the health plan.

**Drug Requested:** Duopa (carbidopa and levodopa enteral suspension) (J7340) (MEDICAL)

**MEMBER & PRESCRIBER INFORMATION:** Authorization may be delayed if incomplete.

Member Name: \_\_\_\_\_

Member AvMed #: \_\_\_\_\_ Date of Birth: \_\_\_\_\_

Prescriber Name: \_\_\_\_\_

Prescriber Signature: \_\_\_\_\_ Date: \_\_\_\_\_

Office Contact Name: \_\_\_\_\_

Phone Number: \_\_\_\_\_ Fax Number: \_\_\_\_\_

NPI #: \_\_\_\_\_

**DRUG INFORMATION:** Authorization may be delayed if incomplete.

Drug Name/Form/Strength: \_\_\_\_\_

Dosing Schedule: \_\_\_\_\_ Length of Therapy: \_\_\_\_\_

Diagnosis: \_\_\_\_\_ ICD Code, if applicable: \_\_\_\_\_

Weight (if applicable): \_\_\_\_\_ Date weight obtained: \_\_\_\_\_

- ☐ Standard Review. In checking this box, the timeframe does not jeopardize the life or health of the member or the member's ability to regain maximum function and would not subject the member to severe pain.

**Recommended Dosage:** The maximum recommended daily dosage is 2,000 mg of the levodopa component (one cassette, 100 mL per day) administered over 16 hours

**Quantity Limit:** 4 cartons (3000 billable units) every 28 days; 1 billable unit = 100 mL

**CLINICAL CRITERIA:** Check below all that apply. All criteria must be met for approval. To support each line checked, all documentation, including lab results, diagnostics, and/or chart notes, must be provided or request may be denied.

**Initial Authorization:** 12 months

(Continued on next page)

- ☐ Prescribed by or in consultation with a neurologist
- ☐ Member is 18 years of age or older
- ☐ Member has a diagnosis of advanced Parkinson's disease (PD) with complicated motor fluctuations
- ☐ Member does **NOT** have a diagnosis of atypical PD or secondary PD
- ☐ Requested medication will be administered via a percutaneous endoscopic gastrostomy with jejunal tube (PEG-J) or naso-jejunal tube
- ☐ Member is experiencing “off” episodes such as muscle stiffness, slow movements, or difficulty starting movements
- ☐ Provider has submitted documentation which confirm member’s symptoms have **NOT** been adequately controlled with optimal medical therapy using **ALL** the following agents:
  - ☐ An oral extended-release carbidopa-levodopa therapy
  - ☐ Dopamine agonist (e.g., Apokyn<sup>®</sup>, Neupro<sup>®</sup>, pramipexole, ropinirole)
  - ☐ **ONE** agent from any of the following classes:
    - ☐ Catechol-O-methyl transferase (COMT) inhibitor (e.g., entacapone, Ongentys<sup>®</sup>, tolcapone)
    - ☐ Monoamine oxidase B (MAO-B) inhibitor (e.g., rasagiline, selegiline, Xadago<sup>®</sup>)
    - ☐ Adenosine receptor antagonist (e.g., Nourianz<sup>®</sup>)
- ☐ Member is **NOT** currently taking a nonselective MAO inhibitor (such as phenelzine or tranylcypromine)

**Reauthorization: 12 months.** Check below all that apply. All criteria must be met for approval. To support each line checked, all documentation, including lab results, diagnostics, and/or chart notes, must be provided or request may be denied.

- ☐ Member continues to meet all initial authorization criteria
- ☐ Provider has submitted documentation which confirms member has experienced clinically significant improvement or stabilization in clinical signs and symptoms of disease

**Medication being provided by (check applicable box(es) below):**

- ☐ Physician's office                      OR                      ☐ Specialty Pharmacy

For urgent reviews: Practitioner should call AvMed Pre-Authorization Department if they believe a standard review would subject the member to adverse health consequences. AvMed’s definition of urgent is a lack of treatment that could seriously jeopardize the life or health of the member or the member’s ability to regain maximum function.

***\*\*Use of samples to initiate therapy does not meet step edit/ preauthorization criteria.\*\****

***\*Previous therapies will be verified through pharmacy paid claims or submitted chart notes.\****